Drug intelligence / Profile preview

xingzaoruanjian

Development stage: Phase 3
Lead developer: Shanghai University of Traditional Chinese Medicine
Modality: Small Molecules
Administration: Oral

Overview

XingZaoRuanJian is a traditional Chinese herbal medicine developed by Shanghai University of Traditional Chinese Medicine. It has been investigated primarily for use in combination with chemotherapy for the treatment of advanced non-small cell lung cancer (NSCLC). The drug is classified as a Chinese patent medicine and is used within integrative oncology approaches. Its precise mechanism of action and molecular targets are not specified in available sources. Clinical trials have evaluated its efficacy and safety when combined with standard chemotherapeutic agents in NSCLC patients[1][2][3].

Brand names: xingzaoruanjianruanhuatang
Other names: xingzaoruanjianruanhuatang

Beyond the preview

Go deeper on xingzaoruanjian.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on xingzaoruanjian.

Explore the full profile